Amphiregulin antibodies and their use to treat cancer and psoriasis
US7223393B2 · kind B2 · utility
8Cited by
7References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 6, 2004 |
| Grant date | May 29, 2007 |
| Priority date | — |
| Expiry date | Feb 6, 2024 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/485
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to anti-AR antibodies, preferably humanized monoclonal antibodies having the amino acid sequences disclosed herein. The present invention includes a pharmaceutical composition comprising such antibodies. The present invention includes a method of inhibiting cancer cell growth comprising administering such antibodies into a subject. The present invention also provides a method of treating cancer or psoriasis in a subject in need of such a treatment by administering such antibodies to said subject in a pharmaceutically effective amount.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.